Cabazitaxel-d9

Cabazitaxel-d9 is deuterium labeled Cabazitaxel. Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.

Product Specifications

CAS Number

[1383572-19-7]

Product Name Alternative

XRP6258-d9; RPR-116258A-d9; taxoid XRP6258-d9

UNSPSC

12352005

Hazard Statement

H302+H312+H332, H315, H319

Target

Autophagy; Isotope-Labeled Compounds; Microtubule/Tubulin

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.4

Solubility

DMSO : 100 mg/mL (ultrasonic; warming)

Smiles

CC(O[C@]12[C@@]3([H])[C@@H]([C@]4(C(C)(C([C@H](C([C@@]3([C@H](C[C@@]1([H])OC2)OC)C)=O)OC)=C([C@H](C4)OC([C@H](O)[C@H](C5=CC=CC=C5)NC(OC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)=O)C)C)O)OC(C6=CC=CC=C6)=O)=O

Molecular Formula

C45H48D9NO14

Molecular Weight

844.99

Precautions

H302+H312+H332, H315, H319

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond) . 2017 Sep;12 (17) :2083-2095.|[3]Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29.